logo
Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage list

Generic Wegovy, Ozempic compounds may become harder to get as FDA removes drug from shortage list

USA Today21-02-2025

Bhanvi Satija, Puyaan Singh, Patrick Wingrove
Reuters
Hear this story
Feb 21 (Reuters) - The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's NOVOb.CO popular weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail widespread sales of cheaper copies made by compounding pharmacies.
Shares of Hims & Hers Health HIMS.N, which advertised its compounded versions of weight-loss drugs during the Super Bowl this month, plunged 22% to $52, on a day it announced the purchase of a plant to make the class of drugs that includes Wegovy and Ozempic.
U.S. regulations allow compounding pharmacies to copy brand-name medicines that are in short supply. Wegovy and Ozempic, both known chemically as semaglutide, were in shortage in the U.S. for much of last year.
More on semaglutide compounds:Shortage of popular drugs Wegovy and Ozempic is over, FDA says.
Americans who cannot afford Wegovy or have struggled to find it have been turning to often cheaper versions sold by pharmacies and telehealth providers like Hims & Hers and WeightWatchers WW.O. Wegovy has been shown to help patients lose as much as 15% of their weight on average.
Need a break? Play the USA TODAY Daily Crossword Puzzle.
WeightWatchers shares were up 5.2% at 77 cents.
Compounders have 60 to 90 days to stop sales
For Hims and other compounders, this development starts the clock on having unfettered market access to Novo's drugs, Leerink Partners analyst Michael Cherny said in a note.
The sale of compounded versions of Eli Lilly's LLY.N rival obesity and diabetes drugs, Zepbound and Mounjaro, was banned in December after the FDA found them to no longer be in short supply. The FDA said in a statement that compounding pharmacies would be given a grace period of 60 to 90 days, as was the case when Lilly's drugs were declared out of shortage.
Robert Califf, who was FDA commissioner under President Joe Biden, said he did not think the agency's declaration would necessarily end obesity drug compounding.
"There so much money to be made. There's just an endless number of tricks that compounders could use," he said in an interview. "So I don't think it's the end of it, but it certainly will bring us into a new era after the time period has passed and all the lawsuits are finished."
Pharmacies cry foul
Scott Brunner, CEO of the Alliance for Pharmacy Compounding, which represents compounding pharmacists and technicians, questioned whether the FDA took into account the number of patients who will need to transition from compounded drugs to FDA-approved versions before making its announcement.
The Alliance wrote to the FDA last year, saying more than 200,000 prescriptions for semaglutide drugs not manufactured by Novo Nordisk were being filled by U.S. patients each month, and the agency should consider their role in alleviating the obesity drug supply crunch before barring them.
Hims CEO Andrew Dudum said in a posting on X that the company was closely monitoring for potential future shortages of the drugs.
Novo said in a statement that the FDA's assessment confirmed that the U.S. supply of its drugs now meets or exceeds current and projected demand.
U.S. listed shares of the Danish drugmaker rose 6.2% to $88.93.
Novo and Lilly have invested billions to ramp up supply of their treatments, which lagged demand for most of last year.
All doses of Ozempic and Wegovy were listed as available on the FDA's website in October, but the treatments had not been taken off the official shortage list at the time.
The agency usually assesses if all back orders have been filled before deciding on whether a shortage has been resolved.
(Reporting by Bhanvi Satija and Puyaan Singh in Bengaluru, and Patrick Wingrove in New York; Additional reporting by Julie Steenhuysen in Chicago; Editing by Arun Koyyur and Bill Berkrot)

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Lilly Pacts Bar Telehealth Firms From Selling Copycat Zepbound
Lilly Pacts Bar Telehealth Firms From Selling Copycat Zepbound

Bloomberg

timean hour ago

  • Bloomberg

Lilly Pacts Bar Telehealth Firms From Selling Copycat Zepbound

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, diminishing the likelihood of a partnership with one most visible players in the industry, Hims & Hers Health Inc. Hims teamed up with Novo Nordisk A/S in April to offer its rival drug Wegovy at a discounted price to patients who use its platform. The telehealth company — and its investors — had been hoping for a similar agreement with Lilly, which is working with several of Hims' competitors to distribute lower-cost Zepbound.

Fungi concerns prompt recall for certain Orajel, Zicam products
Fungi concerns prompt recall for certain Orajel, Zicam products

USA Today

time2 hours ago

  • USA Today

Fungi concerns prompt recall for certain Orajel, Zicam products

Fungi concerns prompt recall for certain Orajel, Zicam products Church & Dwight said this recall is limited exclusively to certain Zicam and Orajel swab products. Show Caption Hide Caption How to brush your teeth better You can get cleaner teeth with this brushing routine. ProblemSolved, USA TODAY The manufacturer of Orajel teething swabs and Zicam cold relief products has voluntarily issued a nationwide recall due to possible fungal contamination, according to a notice posted by the Food and Drug Administration (FDA). Church & Dwight Co., Inc. announced the recall on Friday, June 6, for certain Zicam Cold Remedy Nasal Swabs, Zicam Nasal AllClear Swabs and Orajel Baby Teething Swabs. The affected products, which were distributed nationwide in the U.S. and Puerto Rico, may contain microbial contamination, identified as fungi, in the cotton swab components. Swabs containing fungi can potentially present "significant risk to the health and safety of consumers," including serious and life-threatening blood infections in consumers whose nasal cavity's mucous membrane lining may be compromised due to inflammation and mechanical injuries, according to the FDA recall notice. The health risks of using the recalled products are highest, and potentially severe or life-threatening, among children and people with compromised immune systems or other underlying medical conditions, according to the notice. What are the recalled Church & Dwight products? According to Church & Dwight, the recalled products include: Zicam Cold Remedy Nasal Swabs, with UPC 732216301205, all lots: A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. A zinc-free, homeopathic cold remedy swab designed to shorten the duration of the common cold. Zicam Nasal AllClear Swabs, with UPC 732216301656, all lots: A nasal cleansing swab product that was discontinued in December 2024. A nasal cleansing swab product that was discontinued in December 2024. Orajel Baby Teething Swabs, with UPC 310310400002, all lots: Pre-moistened swabs designed to soothe teething discomfort in infants and toddlers. What should consumers do? Individuals who have bought any of the recalled Church & Dwight products should stop using them immediately, according to the consumer goods company. Consumers can visit or call its consumer relations team at (800) 981-4710 for a full refund. Any additional questions can also be directed to its consumer relations team Monday through Friday, 9 a.m. – 5 p.m. ET. Adverse reactions or quality problems experienced while using the recalled products can be reported to the FDA's MedWatch Adverse Event Reporting program online, by regular mail or by fax. Individuals can complete and submit the report online. According to Church & Dwight, this recall is limited exclusively to Zicam and Orajel swab products. All other Zicam and Orajel products, including Zicam RapidMelts, are not affected by this recall.

"We dissent": NIH scientists sign declaration against Trump's research cuts
"We dissent": NIH scientists sign declaration against Trump's research cuts

Yahoo

time2 hours ago

  • Yahoo

"We dissent": NIH scientists sign declaration against Trump's research cuts

National Institute of Health scientists signed a declaration decrying the cuts to healthcare and medical research by the Trump administration on Monday. Ninety-two scientists added their names to a letter, the Bethesda Declaration, which calls out the Trump administration's handling of the NIH and the cutting of more than 2,100 research grants and contracts, totaling more than $12 billion in federal funding. The letter, named for NIH's headquarters in Maryland, expresses the scientists' "dissent" and outrage over Trump administration policies "that undermine the NIH mission, waste public resources, and harm the health of Americans and people across the globe." The declaration points to canceled studies, including work on the long-lasting effects of COVID-19 and climate change-related health impacts. "Ending a $5 million research study when it is 80% complete does not save $1 million," the declaration states, "it wastes $4 million." Along with the 92 named signatories, more than 250 scientists at the NIH signed the declaration anonymously. "We include anonymous signers and speak for countless others at NIH," the letter concluded, "who share our concerns but who — due to a culture of fear and suppression created by this Administration — chose not to sign their names for fear of retaliation."The declaration was delivered to NIH Director Jay Bhattacharya on Monday. Bhattacharya said the declaration "has some fundamental misconceptions about the policy directions the NIH has taken in recent months." "Nevertheless," he continued, "respectful dissent in science is productive. We all want the NIH to succeed."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store